YnetnewsHealth
New Drug Combo Dramatically Cuts Death Risk in Aggressive Lung Cancer
Summarized from Ynetnews by baba
CenterCharged tone
A new combination therapy of tarlatamab and durvalumab has shown a 58% reduction in death risk for extensive-stage small cell lung cancer patients in a major trial. The treatment extended median survival to 21.1 months from 12.7 months compared to durvalumab alone. Published in the New England Journal of Medicine, the results were presented at an oncology conference in Madrid. While effective, the combination also increased severe side effects, and cost may be a significant factor.
The story in 6 lines · by baba
- New drug combination cuts death risk by 58% in aggressive lung cancer trial.
- Median survival extended by over eight months, reaching 21.1 months.
- Treatment combines tarlatamab with immunotherapy drug durvalumab.
- Results presented at international oncology conference in Madrid.
- Trial involved 563 patients across 29 countries.
- Increased severe side effects noted, but benefits are significant.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.
Mentioned
